-
公开(公告)号:US10280153B2
公开(公告)日:2019-05-07
申请号:US15979849
申请日:2018-05-15
发明人: JinPu Shi , Roberto Profeta
IPC分类号: C07D401/14 , C07D233/61
摘要: Object of the present invention is a process for the preparation of the pharmaceutical active ingredient Nilotinib free base or Nilotinib dihydrochloride dihydrate by means of an improved crystallization procedure.
-
公开(公告)号:US10155740B2
公开(公告)日:2018-12-18
申请号:US15560723
申请日:2016-11-24
IPC分类号: C07D401/04 , A61P35/00
摘要: The present invention relates to novel solid crystal forms of Pomalidomide named Form B, Form M, Pomalidomide:Gentisic acid co-crystal and their preparation. Advantageously, these solid forms are used in pharmaceutical compositions for the treatment and the prevention of multiple myeloma, of inflammatory diseases, of autoimmune diseases, of immune diseases, of myelodysplastic syndrome, of myeloproliferative disorders, of anemia, of scleroderma, amyloidosis or of other diseases associated with unwanted angiogenesis.
-
公开(公告)号:US20180334449A1
公开(公告)日:2018-11-22
申请号:US15979849
申请日:2018-05-15
发明人: JinPu SHI , Roberto PROFETA
IPC分类号: C07D401/14
CPC分类号: C07D401/14 , C07B2200/13
摘要: Object of the present invention is a process for the preparation of the pharmaceutical active ingredient Nilotinib free base or Nilotinib dihydrochloride dihydrate by means of an improved crystallization procedure.
-
公开(公告)号:US20180230151A1
公开(公告)日:2018-08-16
申请号:US15429278
申请日:2017-02-10
发明人: Marco Galvagni , Ennio Grendele , Giovanni Lora
IPC分类号: C07D487/04 , A61K31/4985 , C12P7/26
CPC分类号: C07D487/04 , A61K31/4985 , C12P7/26
摘要: An improved process for the preparation of Triazole and salts thereof, a key intermediate for the synthesis of Sitagliptine is disclosed.
-
公开(公告)号:US10040793B2
公开(公告)日:2018-08-07
申请号:US15827712
申请日:2017-11-30
发明人: Elena Brasola , Filippo Tomasi
IPC分类号: C07D401/14 , C07D471/04 , G01N30/86 , G01N30/02
摘要: Object of the present invention is an improved process for the preparation of Apixaban, through new intermediates which undergo to a faster amidation reaction. Impurities of Apixaban are also identified and quantified.
-
公开(公告)号:US09970042B2
公开(公告)日:2018-05-15
申请号:US15206582
申请日:2016-07-11
发明人: Alfredo Paio , Stefano Fogal , Riccardo Motterle
CPC分类号: C12P33/005 , C07J9/00 , C12N9/20 , C12P33/18 , C12Y301/01003
摘要: The present invention relates to a new process for the preparation of testosterone by means of enzymatic hydrolysis of testosterone esters.
-
公开(公告)号:US20180118737A1
公开(公告)日:2018-05-03
申请号:US15561285
申请日:2016-07-18
发明人: Elena BRASOLA , Filippo TOMASI , Loris PERUZZI
IPC分类号: C07D471/04 , C07D413/04 , C07D413/14 , C07B63/00 , B01D11/02 , G01N30/36 , G01N30/72
CPC分类号: C07D471/04 , B01D11/02 , C07B63/00 , C07D413/04 , C07D413/14 , G01N30/36 , G01N30/7233 , G01N2030/027
摘要: Object of the present invention are dimer impurities of the active ingredient Apixaban, analytical methods for identifying and/or quantifying them and a synthetic method for removing or limiting said impurities from Apixaban and synthetic precursors thereof.
-
38.
公开(公告)号:US20180099944A1
公开(公告)日:2018-04-12
申请号:US15560723
申请日:2016-11-24
IPC分类号: C07D401/04 , A61P35/00
CPC分类号: C07D401/04 , A61P35/00 , C07B2200/13
摘要: The present invention relates to novel solid crystal forms of Pomalidomide named Form B, Form M, Pomalidomide:Gentisic acid co-crystal and their preparation. Advantageously, these solid forms are used in pharmaceutical compositions for the treatment and the prevention of multiple myeloma, of inflammatory diseases, of autoimmune diseases, of immune diseases, of myelodysplastic syndrome, of myeloproliferative disorders, of anemia, of scleroderma, amyloidosis or of other diseases associated with unwanted angiogenesis.
-
公开(公告)号:US09688658B1
公开(公告)日:2017-06-27
申请号:US15501329
申请日:2016-02-23
发明人: Paolo Stabile , Diego Rasia , Nicola Faccin , Moreno Bertolazzi
IPC分类号: C07D401/12
CPC分类号: C07D401/12 , C07B2200/07
摘要: An efficient process for increasing the optical purity of the active pharmaceutical ingredient Esomeprazole, by means of a substantially quantitative and selective precipitation and removal of Omeprazole is provided.
-
40.
公开(公告)号:US20170008861A1
公开(公告)日:2017-01-12
申请号:US15116332
申请日:2015-05-07
IPC分类号: C07D265/18
CPC分类号: C07D265/18
摘要: An improved process for the preparation of Efavirenz which avoids the distillations of the solvents is provided.
摘要翻译: 提供了一种改进的避免溶剂蒸馏的依法韦仑制备方法。
-
-
-
-
-
-
-
-
-